How to read a pharma R&D pipeline like an analyst

What a pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → chart actually shows you

A pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → chart lists a company's drug candidates by development stage:

• Preclinical: lab and animal testing, not yet in humans.
• Phase 1: small human trials (tens of people), testing safety and dosing.
• Phase 2: hundreds of patients, testing efficacy signals.
• Phase 3: hundreds to thousands of patients, the pivotal trial regulators need to approve a drug.
• Filed / Under Review: the company has submitted a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA (US Food and Drug Administration), or a Marketing Authorisation Application (MAA) to the EMA (European Medicines Agency).

The chart tells you *where* a drug sits. It tells you nothing about the *odds* it survives to the next stage, or what it's worth if it does. That's your job.

Probability of success (PoS): the core number

Probability of Success (PoS) is the estimated likelihood a candidate advances from its current phase all the way to approval. Analysts build it from historical base rates by phase and therapeutic area, published in large academic studies.

The most widely cited benchmark comes from a Biotechnology Innovation Organization (BIO) study analyzing over 9,000 clinical programs, covering 2011 to 2020. Rough industry-standard estimates derived from this and similar work (treat as estimates, they vary by source and year):

| Transition | Approx. success rate (estimate) |

|---|---|

| Phase 1 → Phase 2 | ~52% |

| Phase 2 → Phase 3 | ~28-30% |

| Phase 3 → Filing/Approval | ~57-65% |

| Overall Phase 1 → Approval, all diseases | ~7-10% |

| Overall Phase 1 → Approval, oncology specifically | ~3-5% |

Oncology is the hard case: more targets fail, tumors mutate resistance, and regulators demand strong survival data. That's precisely why oncology pipelines need this lens most.

Worked calculation: chaining phase probabilities

Say a company has an oncology drug in Phase 2. To estimate its odds of reaching approval, multiply the remaining phase-transition probabilities:

• Phase 2 → Phase 3: 30%
• Phase 3 → Filing: 60%
• Filing → Approval: 90% (approval-stage attrition is typically low once filed)

Cumulative PoS = 0.30 × 0.60 × 0.90 = 16.2%

So a drug sitting comfortably in Phase 2 on a glossy pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → slide has, on these industry averages, roughly a 1-in-6 chance of ever being approved. That's the number the chart doesn't show you.

From PoS to risk-adjusted NPVNPVNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.Voir la définition complète → (rNPV)

Once you have PoS, you can risk-adjust a drug's future cash flows to value it honestly. This is risk-adjusted Net Present Value (rNPV), the standard valuation method for pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → assets that generate no revenue yet.

Simplified formula:

Where:

• Projected Cash Flow = peak sales forecast minus costs (R&D, manufacturing, commercialization) in each future year.
• Cumulative PoS = the chained probability from above.
• Discount rate = reflects cost of capital and risk; biotech analysts commonly use 10-14% (estimate, varies by company risk profile and stage).

Worked Example

A Phase 2 oncology drug is forecast to generate $500 million in risk-free peak-year cash flow, occurring in year 8, if approved. Cumulative PoS is 16.2% (from above). Discount rate: 12%.

Compare that to the "undiscounted, unrisked" headline number some investor decks imply ($500M) and you see why rNPV routinely produces valuations 80-95% lower than the sales figure quoted in a press release. In practice, analysts sum this calculation across every year of the sales curve, not just peak year, but the single-year version shows the mechanics clearly.

Why this differs by region: US vs. europe

PoS and commercial value both shift depending on regulatory geography.

• US (FDA): larger single market, historically faster approval timelines via pathways like Priority Review (target decision in ~6 months vs. standard ~10 months) and Breakthrough Therapy Designation. US net drug prices are typically higher, boosting projected cash flows.
• Europe (EMA): centralized EMA approval doesn't guarantee reimbursement. Each country then negotiates price and reimbursement separately (Germany's IQWiG/G-BA process, France's HAS, UK's NICE via a distinct post-Brexit process). This adds a second layer of "success" risk beyond regulatory approval: a drug can be approved by EMA and still get rejected for reimbursement in a major market, which materially cuts the realistic cash flow analysts should plug into rNPV.

Analysts often build separate PoS-and-cash-flow tracks for US and EU launches rather than blending them.

Reading a real pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → chart: a checklist

When you see a pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → slide, ask:

1. What phase, exactly? "Phase 2" spanning a single-arm signal-finding study is riskier than "Phase 2" nearly complete with a randomized controlled design.

2. What's the indication? Oncology and CNS (central nervous system, e.g., Alzheimer's) have historically lower PoS than, say, infectious disease or rare/orphan disease (which often benefit from smaller trials and faster regulatory pathways).

3. Is there already a validated mechanism? A "me-too" or biosimilar-adjacent drug targeting a mechanism already proven by a competitor's approval carries meaningfully higher PoS than a first-in-class novel target.

4. What does the company assume for peak sales, and is that consensus or company-only? Compare against independent analyst consensus where available (e.g., via EvaluatePharma or sell-side equity research) rather than management's own slide.

Putting it together: a mini case pattern

Imagine a mid-cap biotech with three oncology assets:

• Asset A: Phase 3, validated target (a kinase inhibitor class with prior approvals). Estimate PoS to approval: ~55%.
• Asset B: Phase 2, novel first-in-class immuno-oncology mechanism. Estimate PoS: ~12%.
• Asset C: Phase 1, novel target, no human efficacy data yet. Estimate PoS: ~5%.

If the company's investor deck presents all three with equal visual weight and similar "blockbuster potential" language, your rNPV math should tell a very different story: Asset A likely carries the overwhelming majority of the company's actual risk-adjusted value, even if Assets B and C get more airtime as "innovative" growth drivers. This is the standard analyst move: rank pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → assets by rNPV contribution, not by phase count or slide real estate.

🎬 [VIDEO: "Biotech Valuation: Risk-Adjusted NPVNPVNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.Voir la définition complète → Explained" - youtube.com - search for recent biotech equity research or valuation-focused channels explaining rNPV mechanics with a walked-through example]

For a deeper primer on trial design that underpins these probabilities, ClinicalTrials.gov lets you check a real company's actual trial phase, enrollment size, and design, useful for sanity-checking any pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → slide against the underlying registered study.

Key Takeaways

• Pipeline charts show location, not likelihood. Always ask what phase-transition probability applies before believing a growth story.
• Chain phase probabilities to get cumulative PoS. A Phase 2 oncology asset typically carries roughly a 15-20% chance of eventual approval, using industry-average estimates, far lower than a chart's confident visual implies.
• rNPV = risk-adjusted, discounted cash flow. It routinely values pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → assets at a fraction of the "peak sales" number quoted in press releases; expect 80%+ haircuts as standard, not a red flag.
• Region changes the math. US pricing tends to lift cash flow assumptions; Europe's added reimbursement-negotiation layer (NICE, G-BA, HAS, etc.) adds a second risk gate beyond EMA approval.
• Rank assets by rNPV contribution, not phase. The asset getting the least airtime on stage may be carrying most of the company's real value, or vice versa.